|
Patent landscape, scope, and claims: |
US Patent 9,545,457 Scope and Claim Construction: DPPA/DPPC/MPEG5000-DPPE Perfluoropropane Ultrasound Contrast Agents for Echocardiography
Executive summary
- US 9,545,457 claims a specific microbubble ultrasound contrast formulation and its use in a method for enhancing contrast in echocardiographic ultrasound images by using that agent.
- The independent claim is anchored on four composition constraints:
- Excipients/vehicle (NaCl, glycerin, propylene glycol, water),
- Perfluoropropane gas payload,
- A defined phospholipid system (DPPA + DPPC + MPEG5000-DPPE), and
- Hard numeric bounds: mole ratio “10% to 82% to 8%” and lipid amount about 0.75 mg/mL.
- The claim scope is narrower than “perfluoropropane + PEGylated phospholipid” generally marketed for echocardiography because it requires the specific PEGylated lipid identity and DPPA/DPPC proportions plus the approximate concentration and specific formulation excipients.
What does US 9,545,457 claim: method using DPPA/DPPC/MPEG5000-DPPE perfluoropropane ultrasound contrast for echocardiography?
Claim type and structure
- The claim is a method claim: “A method comprising using an ultrasound contrast agent to enhance contrast in an echocardiographic ultrasound image of a subject…”
- It is use-driven but the novelty sits largely in the composition recitations of the ultrasound contrast agent.
Key limiting elements (directly from claim 1)
- Imaging context: echocardiographic ultrasound image of a subject.
- Payload gas: perfluoropropane (C3F8).
- Phospholipid blend identity:
- DPPA: 1,2-dipalmitoyl-sn-glycero-3-phosphotidic acid, mono sodium salt
- DPPC: 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine
- MPEG5000-DPPE: N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt
- Phospholipid ratio constraint: “present in a mole ratio of 10% to 82% to 8% to 8%”
- The claim text as provided contains repeated “to 8%” and likely reflects a transcription/parsing artifact. In claim construction practice, the intended meaning is typically a three-component ratio among DPPA, DPPC, and MPEG5000-DPPE. The provided sequence reads as DPPA:DPPC:MPEG5000-DPPE with target ranges anchored at 10% / 82% / 8%.
- Total lipid concentration: “present in an amount of about 0.75 mg/mL.”
- Aqueous formulation excipients (as recited):
- sodium chloride
- glycerin, about 0.1 mL/mL
- propylene glycol, about 0.1 mL/mL
- water
- Net dosage form limitation: the agent as a “contrast agent” meeting the above formulation.
What the method claim actually requires
- To infringe, an accused process must use an ultrasound contrast agent that matches the composition limitations. A method of imaging with a different microbubble formulation (different PEG-lipid, different phospholipid ratios, different total lipid concentration, different gas, or without the specified excipient system) is outside the claim’s literal scope.
How do courts likely interpret the “mole ratio 10% to 82% to 8%” and “about 0.75 mg/mL” limitations?
Ratio language: “mole ratio”
- “Mole ratio” typically means the proportion of each lipid component expressed by mole fraction (not weight fraction).
- If the intended three-component ratio is DPPA:DPPC:MPEG5000-DPPE ≈ 10:82:8, infringement hinges on whether the accused formulation’s mole fractions fall within the claim’s express range boundaries (as stated in the claim).
“about” language
- “about 0.75 mg/mL” introduces tolerance. In practice, “about” invites a factual range based on specification and prosecution history, but the claim remains composition-limited.
- A meaningful non-infringing design-around often changes total phospholipid concentration well outside the “about” zone, or changes at least one of the three lipid identities.
What is the scope of “echocardiographic ultrasound image” limitation in US 9,545,457?
Imaging modality
- The claim limits use to echocardiographic ultrasound images. That narrows application compared to claims covering “ultrasound imaging” broadly.
- A process using the same microbubble formulation for non-echocardiography ultrasound (for example, abdominal ultrasound) would not meet the imaging-context limitation.
Subject and method steps
- The “method comprising using” phrasing makes the act of using the formulation to enhance echocardiographic contrast the core step.
- The claim does not recite dosing volume, scan timing, or clinical endpoints. That increases scope for infringing “use” so long as the composition matches.
Which components are essential for literal infringement: DPPA vs DPPC vs MPEG5000-DPPE vs perfluoropropane?
Gas: perfluoropropane
- The claim requires perfluoropropane as the gas phase.
- Designs using a different fluorinated gas (for example, perfluorobutane, perfluorohexane, SF6) do not satisfy this element.
Phospholipid identities
- DPPA is required. Many prior art microbubbles use phosphatidylcholines with or without charged lipids, but substitution changes literal scope.
- DPPC is required. Replacing DPPC with another phosphatidylcholine (for example, distearoyl-PC) would likely avoid literal infringement.
- MPEG5000-DPPE is required. Many competitor formulations use PEGylated lipids with different PEG chain lengths or different PEG-lipid backbones. Changing PEGylated lipid identity or PEG length can create non-infringing alternatives, especially if it avoids the exact “MPEG5000-DPPE” structure.
Excipient system
- The presence of NaCl, glycerin (about 0.1 mL/mL), propylene glycol (about 0.1 mL/mL), water is part of the recited agent.
- Many prior art contrast formulations use buffers, sugars, or different cryoprotectants. Those differences can avoid literal infringement.
What formulations are covered: microbubble/contrast agent composition and concentration constraints?
Covered formulation space (as pleaded in claim 1)
- Lipid shell: DPPA + DPPC + MPEG5000-DPPE at an explicit mole ratio centered around 10% / 82% / 8% (based on the claim text provided).
- Total lipid: about 0.75 mg/mL.
- Gas: perfluoropropane.
- Carriers/lyoprotectants: NaCl + glycerin + propylene glycol + water.
Not claimed (based on the single claim’s text)
- No explicit mention of:
- lyophilized vs liquid packaging,
- particle size distribution,
- shell thickness,
- surfactant beyond the listed lipids,
- targeting ligands,
- method timing (e.g., post-injection peak enhancement),
- dosing regimen.
As a result, the claim stays focused on the agent composition and use in echocardiography.
How strong is the patent estate for this formulation: what additional claim dependents would normally do?
Constraint: only claim 1 text is provided
- Patent strength analysis for the estate depends on:
- whether there are dependent claims that broaden to ranges (wider ratio windows, different concentrations),
- whether there are method variants covering other echo indications,
- whether formulation claims include alternative excipients or delivery formats.
Because the dataset includes only claim 1, the estate strength can be assessed only at the level of the independent method claim’s narrow, composition-defined scope. In general, narrow independent claims can still create leverage if dependent claims add coverage across commercially realistic variations.
How does US 9,545,457 compare with competing echocardiography ultrasound contrast microbubble patent families?
Common industry claim patterns
Most ultrasound contrast microbubble patent families for US markets cluster around:
- specific gas payloads (perfluoropropane, perfluorobutane, etc.),
- specific shell compositions (lipid identity and PEG-lipid chemistry),
- formulation excipients (buffers, glycerin/PG-like stabilizers),
- use claims (echocardiography, perfusion imaging, myocardial studies).
Practical comparison to claim scope
- US 9,545,457 is distinguishable from “broad” prior art by the combination of:
- a required charged lipid (DPPA),
- a required specific PEGylated lipid (MPEG5000-DPPE),
- a required explicit mole ratio,
- and a required specific excipient system plus total lipid concentration.
Competitors with similar gases but different shells may avoid literal infringement.
What are the generic and biosimilar entry risks for ultrasound contrast agents after US 9,545,457?
Regulatory pathway implications
- Ultrasound contrast microbubbles are typically regulated via NDA or potentially ANDA-like frameworks depending on product class; “biosimilar” concepts apply to biologics, but many microbubble products are treated as drug products with complex manufacturing. The practical risk posture for generic-style entrants is usually tied to:
- ability to reproduce the composition and performance,
- ability to demonstrate sameness or bioequivalence under the applicable regulatory framework,
- and patent landscape barriers around formulation and use.
Entry risk under this specific claim
- For US 9,545,457 specifically, the most direct risk to entrants is adoption of a microbubble that matches:
- DPPA/DPPC/MPEG5000-DPPE proportions (mole ratio),
- total phospholipid concentration (about 0.75 mg/mL),
- perfluoropropane payload,
- and the glycerin/propylene glycol excipient amounts.
If a generic applicant changes one or more of these, literal infringement risk declines quickly. If it changes them slightly, doctrine-of-equivalents arguments become the battleground, but the claim’s numeric ratio and identity requirements generally make equivalency harder.
What patent litigation issues typically drive exposure for composition-defined method claims like US 9,545,457?
Likely infringement themes
- Element-by-element composition match: lipid identity (DPPA, DPPC, MPEG5000-DPPE), gas identity, and concentration/ratio.
- Process-to-formulation mapping: proving that the accused product contains the asserted lipid blend and excipients at the claimed levels.
- Claim construction:
- whether “mole ratio of 10% to 82% to 8%” is treated as fixed or range,
- how “about 0.75 mg/mL” is interpreted,
- whether formulation components are “present in an amount” satisfying the claim when minor deviations exist.
Typical defense themes
- Different PEG-lipid identity or PEG chain length.
- Different phosphatidic acid salt form or different charged lipid altogether.
- Different gas payload.
- Different excipients or excipient concentrations.
- Different lipid concentration outside “about.”
Orange Book status and exclusivity timelines for US 9,545,457
Constraint: no product/Orange Book listing mapping was provided
- The analysis cannot state Orange Book status, exclusivity, or expiration timing without the corresponding US NDA/Orange Book identifiers and listed patent numbers. Those details are not present in the prompt.
Key takeaways
- US 9,545,457 claim 1 is a composition-constrained method claim: it covers using a perfluoropropane ultrasound contrast agent containing DPPA + DPPC + MPEG5000-DPPE in an explicit mole ratio and at about 0.75 mg/mL total lipid, formulated with NaCl + glycerin + propylene glycol + water, for enhancing echocardiographic images.
- The claim’s numeric ratio and concentration limits plus the requirement for specific lipid identities (including MPEG5000-DPPE) materially narrow infringement exposure.
- Competitive and generic-style entry risk is highest if a candidate formulates a microbubble that matches the exact lipid system and excipient framework in addition to using perfluoropropane for echocardiography.
FAQs
1) What would be the fastest non-infringing design change vs US 9,545,457?
Replacing at least one required element, most effectively the gas (perfluoropropane) or the PEGylated lipid identity (MPEG5000-DPPE), or moving the DPPA/DPPC/MPEG5000-DPPE mole fractions and total lipid concentration outside the claim’s “about” and ratio limitations.
2) Does US 9,545,457 cover use of the same contrast agent for non-cardiac ultrasound?
No, the claim requires the contrast enhancement of an echocardiographic ultrasound image.
3) Are “about” ranges likely to be broad enough to cover minor formulation changes?
The “about 0.75 mg/mL” term allows some tolerance, but infringement still requires a formulation that remains close enough to meet the court’s interpretation, with the ratio limitation typically remaining a strong, factual constraint.
4) What’s the main evidentiary burden in enforcing this claim?
Proving the accused product’s actual composition, including lipid identity, mole ratio, total lipid concentration, gas payload, and excipients (NaCl, glycerin, propylene glycol, water).
5) Does the claim require targeting ligands, particle size, or specific dosing?
No. Claim 1 focuses on the agent composition and its use for echocardiographic contrast; it does not recite particle size, targeting, or dosing.
References
- US Patent No. 9,545,457. (Claims provided in prompt text).
More… ↓
⤷ Start Trial
|
